Published 1 year ago

Eisai files for full FDA approval for Alzheimer's drug Leqembi

Summary by Ground News

Japanese drugmaker Eisai Co Ltd (4523.T) says it has submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi. The drug was recently approved under the agency's accelerated review process.

0 Articles

All

Left

Center

Right

Reuters

Eisai files for full FDA approval for Alzheimer's drug Leqembi

Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved under the agency's accelerated review process.

1 year ago·United Kingdom

Read Full Article

The News

US approves new drug to treat Alzheimer's disease

WASHINGTON: The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.The...

1 year ago·Pakistan

Read Full Article

Financial Post

Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval

The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease.

1 year ago·Canada

Read Full Article

OAN

Eisai files for full FDA approval for Alzheimer's drug Leqembi

(Reuters) - Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved

1 year ago·San Diego, United States

Read Full Article

Bisnis.com

FDA Approves Leqembi Drug, New Therapy for Alzheimer's Sufferers

The FDA approved the drug Leqembi as a treatment for people with mild and early stages of Alzheimer's on Friday (6/1/2023).

1 year ago

Read Full Article

The Manila Times

US approves new drug to treat Alzheimer's disease

THE US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized in a congressional report for its green-lighting of another Alzheimer's drug, Aduhelm.And it was granted despite trial results showing the…

1 year ago·Manila, Philippines

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.